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DObjective: With progressive aging, coronary artery disease has been diagnosed at more advanced ages.
Although patients aged 65 years or more have been referred to surgical or percutaneous coronary interventions,
the best option for coronary artery disease treatment remains uncertain. The current study compared the 3 treat-
ment options for coronary artery disease in patients aged 65 years or more and analyzed the impact of age in
treatment options.
Methods: Patients were separated according to age: 65 years or more (n¼ 200) and less than 65 years (n¼ 411).
All patients were followed for 10 years. The rates of overall mortality, acute myocardial infarction, and new
revascularizations were analyzed.
Results:Of 200 patients aged 65 years or more, 68 were randomized to medical therapy, 68 were randomized to
percutaneous coronary intervention, and 64 were randomized to coronary artery bypass grafting. At 10 years,
overall survival was 63% (medical therapy), 69% (percutaneous coronary intervention), and 66% (coronary
artery bypass grafting) (P ¼ .93). The survival free of combined events was 43% (medical therapy), 38%
(percutaneous coronary intervention ), and 66% (coronary artery bypass grafting) (P ¼ .007). The survival
free of myocardial infarction was 82% (medical therapy), 77% (percutaneous coronary intervention), and
90% (coronary artery bypass grafting) (P¼ .17), and survival free of new revascularizations was 59% (medical
therapy), 58% (percutaneous coronary intervention ), and 91% (coronary artery bypass grafting) (P ¼ .0003).
When the 2 age groups were compared, survival free of myocardial infarction for patients treated by percutane-
ous coronary intervention was 77% (older patients) and 92% (younger patients) (P ¼ .004).
Conclusions: In this analysis, treatment options for patients aged 65 years or more who have coronary artery
disease yield similar overall survival. However, coronary artery bypass grafting was associated with fewer cor-
onary events, and percutaneous coronary intervention was associated with a higher incidence of myocardial in-
farction. (J Thorac Cardiovasc Surg 2013;146:1105-12)In recent decades, the world population has become propor-
tionally older. According to the United Nations, by 2050 the
number of people aged 60 years or more in the world will
exceed the number of children (0-14 years) for the first
time in history.1
With the aging of the population, coronary artery disease
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The Journal of Thoracic and Cardemographic change has led to an increase in the number
of older patients referred for coronary revascularization.
However, because of methodological questions, clinical
trials of long-term follow-up have routinely decreased
the number of older patients undergoing mechanical
interventions.2
Older patients with CAD usually have more diffuse,
systemic atherosclerosis.3 In addition, noncardiac comor-
bidities, such as peripheral vascular disease and impaired
renal and pulmonary function, are more prevalent in older
patients,4-6 providing a worse prognosis for interventional
treatment.7,8 This higher-risk profile of older patients with
CAD contributes to their increased complication rates
after both percutaneous coronary intervention (PCI)9 and
coronary artery bypass grafting (CABG).10 Consequently,
several clinical trials have confirmed that a relation exists
between clinical outcomes from either method of mechan-
ical revascularization and the patient’s age.11 However,
other studies suggest that older patients have greater
benefits from mechanical intervention than from medicaldiovascular Surgery c Volume 146, Number 5 1105
Abbreviations and Acronyms
BARI ¼ Bypass Angioplasty Revascularization
Intervention
CABG ¼ coronary artery bypass grafting
CAD ¼ coronary artery disease
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Dtherapy.12 Another study13 concluded that a greater absolute
risk reduction is associated with revascularization in older
compared with younger patients.
Thus, the most appropriate therapeutic strategy for older
patients—PCI, medical treatment (MT), or CABG—re-
mains controversial mainly because of the lack of clinical
studies investigating a direct comparison of the 3 treatment
strategies in these age groups.
This analysis from a 10-year follow-up of the Medicine,
Angioplasty, or Surgery Study (MASS II) aims to compare
the 3 treatment options for CAD in patients aged 65 years or
more and the effect of age on the results of each treatment
strategy.
MATERIALS AND METHODS
Trial Design
The details of the MASS II design, study protocol, patient selection, in-
clusion criteria, and general results have been published.14 Briefly, the
MASS II study was a prospective, randomized, controlled clinical trial de-
signed to compare MT, PCI, and CABG in patients with stable multivessel
CAD and preserved left ventricular function. As previously reported,14
from a total of 20,769 patients with a presumptive diagnosis of CAD
who underwent coronary arteriography at the Heart Institute of the Univer-
sity of Sao Paulo between May 1995 and May 2000, 2077 (10%) had an
indication for coronary revascularization and met the study entry criteria.
The most frequent reasons to exclude patients from the initial population
were single-vessel disease, refractory angina, stenosis 70% or less, previ-
ous PCI or CABG, and valvular disease. Of these 2077 patients, 1466
(71%) could not be randomized because they refused to participate in
this trial or specifically refused the surgical procedure. The remaining
611 patients (29%) were randomly assigned to 1 of the 3 therapeutics:
PCI, MT, or CABG. The predefined primary end point was the combined
incidence of overall mortality, myocardial infarction (MI), or persistent an-
gina requiring additional mechanical revascularization. Patients with an-
giographically documented proximal multivessel coronary stenosis
(>70% of stenosis) by visual assessment and documented ischemia were
considered for inclusion. Patients were enrolled and randomized if the sur-
geons, attending physicians, and interventional cardiologists agreed that re-
vascularization could be attained by one of the strategies. Clinical criteria
of exclusion included unstable angina or acute MI requiring emergency re-
vascularization, ventricular aneurysm requiring surgical repair, left ventric-
ular ejection fraction less than 40%, a history of PCI or CABG,
single-vessel disease, and left main coronary artery stenosis 50% or
greater. Patients also were excluded if they had another coexisting condi-
tion associated with reduced life expectancy. In this trial, all patients
were placed on optimal MT for CAD. This consisted of a stepped-care1106 The Journal of Thoracic and Cardiovascular Surapproach using aspirin, nitrates, beta-blockers, calcium-channel blockers,
angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers,
and statins. All medications were provided for free by the Heart Institute.
Patients were randomized to continue with MTalone or to undergo PCI
or CABG concurrently with MT. Complete revascularization by PCI or
CABG in accordance with current best practices was encouraged but not
mandatory. Patients assigned to PCI had their procedures performed within
3 weeks after randomization. Devices available to the interventionist in-
cluded conventional stents, lasers, directional atherectomy, and balloon an-
gioplasty, if necessary. Each PCI-treated patient had an average of 2.1 0.7
vessels dilated. Patients assigned to CABG had their procedures performed
within 12 weeks after randomization. Revascularization was performed
with the use of saphenous vein grafts, internal thoracic arteries, and other
conduits, such as radial or gastroepiploic arteries. Standard surgical tech-
niques were used with patients under hypothermic arrest with blood cardi-
oplegia. No off-pump CABG was performed. Each patient undergoing
CABG had an average of 3.3 0.8 vessels bypassed. At least 1 internal tho-
racic artery was used for grafting in 92% of patients.
Patients gave written, informed consent and were randomly assigned to
a treatment group. The Ethics Committee of the Heart Institute of the Uni-
versity of S~ao Paulo Medical School (S~ao Paulo, Brazil) approved the trial,
and all procedures were performed in accordance with the Helsinki
Declaration.
Older patients were considered those aged 65 years or more at the time
of randomization. Patients (n¼ 611) were separated according to age into 2
groups: 65 years or more (group 1 ¼ 200) and less than 65 years (group
2¼ 411). All patients were followed up for 10 years. We analyzed the rates
of overall mortality and the occurrence of MI, angina requiring new revas-
cularizations, and combined major events (death, MI, and new revascular-
izations) in group 1.We also analyzed the differences between groups 1 and
2 in terms of major cardiovascular events and in each treatment strategy.
Data Collection and Long-Term Follow-up
Demographic and clinical data were obtained at baseline for all 611 pa-
tients. The collected demographic and laboratory data included sex, ethnic-
ity, traditional risk factors (eg, previous coronary events), hypertension,
diabetes, smoking status (current smokers, never smokers), chronic kidney
disease (defined as creatinine level 1.5), number of diseased coronary
vessels, cholesterol and triglyceride profiles, and renal function.
MI was defined as the presence of significant new Q waves in at least 2
electrocardiogram leads or symptoms compatible with MI associated with
creatine kinase-MB concentrations that were more than 3 times the upper
limit of the reference range.
Adverse and clinical events were tracked from randomization. All mor-
tality events were confirmed by death certificates. Patients were assessed
with follow-up visits every 6 months over 10 years at the Heart Institute.
The minimum length of follow-up for patients alive was 9 years, and the
maximum was 15 years (mean, 11.4 years).
Statistical Analysis
All data were analyzed according to the intention-to-treat principle. Pri-
mary end points were the overall mortality, occurrence ofMI, occurrence of
angina requiring additional mechanical revascularization (PCI or CABG),
and occurrence of combined events (overall mortality,MI, and new revascu-
larizations). The survival free of overall mortality and isolated major events
was defined as the interval between the random assignment and the occur-
rence of death or the major event up to 10 years of follow-up. The survival
free of combined events was defined as the interval between random assign-
ment and the occurrence of the first major event up to 10 years of follow-up.
Event-free survival was estimated by the Kaplan–Meier method, and differ-
ences among agegroups and treatment groupswere assessed bymeans of the
log-rank test. Mean levels of continuous variables were compared by 1-way
analysis of variance, followed by Tukey’s multiple-comparisons test. The
Pearson chi-square test was used to compare qualitative variables betweengery c November 2013
TABLE 2. Baseline characteristics of older patients, according to
treatment option
Groups
MT
(n ¼ 68)
PCI
(n ¼ 68)
CABG
(n ¼ 64)
P
value
Age, mean  SD, y 70.5  3.5 69.9  3.5 69.5  3.2 .20
Female% 39.7 39.7 29.7 .038
White% 76.5 94.1 85.9 .01
Hypertension% 55.9 57.4 64.1 .59
Diabetes mellitus% 33.8 29.4 29.7 .82
Current smoker% 23.5 17.6 21.9 .32
Never smoker% 54.4 55.9 65.6 .32
Previous MI% 36.8 50.0 34.4 .13
3-vessel disease% 35.3 34.3 28.1 .63
CKD% 7.4 8.8 4.7 .64
Total C, mean  SD 227.6  41.9 224.6  43.8 221.6  50.0 .75
LDL-C, mean  SD 151.4  36.7 150.3  36.6 142.8  46.1 .42
HDL-C, mean  SD 39.4  12.7 39.7  10.8 40.5  13.1 .87
TG, mean  SD 172.7  76.1 176.0  98.9 177.3  92.0 .95
Serum creatinine,
mean  SD
1.05  0.2 1.21  0.8 1.09  0.5 .20
MT, Medical therapy; PCI, percutaneous coronary intervention; CABG, coronary
artery bypass surgery; SD, standard deviation; MI, myocardial infarction; CKD,
chronic kidney disease; C, cholesterol; LDL, low-density lipoprotein; HDL,
high-density lipoprotein; TG, triglycerides.
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variables with a possible association (P<.1). Tests were 2-tailed. Statistical
analyseswere performedwith the Statistical Package for the Social Sciences
version 17.0 (SPSS Inc, Chicago, Ill).
RESULTS
Baseline Findings
Patients (n¼ 611) were separated according to age into 2
groups: 65 years or more (group 1 ¼ 200 patients) and less
than 65 years (group 2¼ 411 patients). Baseline data of the
2 age groups are summarized in Table 1.
Compared with group 2, group 1 included more women
(36.5% vs 28.0%, P ¼ .032), had fewer current smokers
(20.5% vs 37.0%, P ¼ .0001), had higher high-density li-
poprotein cholesterol levels (39.9 vs 36.0, P< .001), and
had lower triglyceride levels (175.0 vs 204.9).
Older patients (n ¼ 200) were stratified according to the
randomized treatment into 3 groups: angioplasty, bypass
surgery, or MT alone. The baseline characteristics of the 3
treatment groups were similar with respect to important
prognostic characteristics, except for the higher percentage
of white persons in the PCI-treated group (Table 2).
End Point Events in the Older Group
Of the 200 patients aged 65 years or more, 68 were ran-
domized to MT, 68 were randomized to PCI, and 64 were
randomized to CABG treatment. At the 10-year follow-
up, overall survivals in each treatment strategy were 63%
(MT, 40 patients), 69% (PCI, 41 patients), and 66%
(CABG, 40 patients) (P ¼ .93) (Figure 1, A). The survivals
free of combined events were 43% (MT, 27 patients), 38%
(PCI, 26 patients), and 66% (CABG, 41 patients)
(P ¼ .007) (Figure 1, B). The survivals free of MI wereTABLE 1. Baseline characteristics of 611 patients from the Medicine,
Angioplasty, or Surgery Study II trial, according to age
Groups 65 y (n ¼ 200) <65 y (n ¼ 411) P value
Age, mean  SD, y 70.0  3.4 54.7  6.5
Female% 36.5 28.0 .03
White% 84.5 85.4 .76
Hypertension% 59.5 59.6 .97
Diabetes mellitus% 31.5 30.9 .88
Current smoker% 20.5 37.0 <.001
Never smoker% 58.0 43.1 <.001
Previous MI% 41.0 45.7 .26
3-vessel disease% 67.8 61.0 .10
CKD% 7.0 6.3 .75
Total-C, mean  SD 224.3  45.1 222.6  48.9 .68
LDL-C, mean  SD 147.9  39.8 146.8  44.6 .76
HDL-C, mean  SD 39.9  12.2 36.0  9.0 <.001
TG, mean  SD 175.0  89.2 204.9  132.9 .0043
Serum creatinine,
mean  SD
1.12  0.6 1.09  0.5 .52
SD, Standard deviation;MI, myocardial infarction; CKD, chronic kidney disease; C,
cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; TG,
triglycerides.
The Journal of Thoracic and Car82% (MT, 55 patients), 77% (PCI, 53 patients), and 90%
(CABG, 58 patients) (P ¼ .17) (Figure 1, C), and the sur-
vivals free of new revascularizations were 59% (MT, 43 pa-
tients), 58% (PCI, 41 patients), and 91% (CABG, 58
patients) (P ¼ .0003) (Figure 1, D).
End Point Events in Older Versus Younger
When we compared the older group with the younger
group, in a univariate analysis, the overall survivals were
57% versus 77%, respectively (P< .001; Figure 2, A).
When we compared the older and younger groups in each
treatment strategy, the overall survivals were 57% versus
67% for patients receiving MT (P ¼ .03; Figure 2, B),
52% versus 81% for patients receiving PCI (P ¼ .0002;
Figure 2, C), and 62% versus 80% for patients receiving
CABG (P ¼ .0029; Figure 2, D), respectively. After multi-
variate analysis, overall survivals in these 2 age groups were
still statistically different, 56% versus 78% (P ¼ .0001),
even when treatment groups were analyzed separately.
Older patients had similar survivals free of MI compared
with younger patients, 83% versus 86% (P¼ .09; Figure 3,
A). When treatments were analyzed separately for the older
versus younger groups, survivals free of MI were 82% ver-
sus 79% forMT (P¼ .98; Figure 3,B), 77% versus 92% for
PCI (P ¼ .004; Figure 3, C), 90% versus 89% for CABG
(P¼ .93; Figure 3,D), respectively. After multivariate anal-
ysis, survival results were similar, with higher rates of MI in
PCI-treated elderly patients (survivals free of MI 76% vs
93%, P¼ .0032, in older vs younger patients, respectively).
The survivals free of new revascularizations were similar
between the older and younger groups, 69% versus 72%diovascular Surgery c Volume 146, Number 5 1107
FIGURE 1. Survival without overall death (A) and freedom from major cardiovascular events (B-D) in 10-year follow-up of 200 elderly patients from the
MASS II trial according to treatment strategy (MT, PCI, or CABG): combined events (B), acute MI (C), and angina requiring new interventions (D). CABG,
Coronary artery bypass grafting; MT, medical treatment; PCI, percutaneous coronary intervention.
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treatment strategy, the survivals free of revascularizations
were 59% versus 60% for MT (P ¼ .94), 58% versus
62% for PCI (P ¼ .77), and 90% versus 93% for CABG
(P ¼ .32).
DISCUSSION
With progressive aging, CAD has become more frequent
and its treatment more challenging. With successful aging
and improvement in technical revascularization procedures,
a higher proportion of older patients have been referred for
invasive interventions to relieve angina symptoms and im-
prove life expectancy, although it is still uncertain whether
these interventions are superior to MT alone for the man-
agement of patients aged 65 years or more who have
CAD. In addition, numerous studies demonstrate a higher1108 The Journal of Thoracic and Cardiovascular Surrisk of periprocedural complications related to older
age.2,15-17 Moreover, fewer studies compared the 3
treatment options for CAD in patients aged 65 years or
more. Most of them compared only 2 treatment
options.15,18-20
The MASS II trial is one of the few studies that have
compared the 3 therapeutic options for CAD. One third
of MASS II trial patients were aged 65 years or more at
the time of the randomization. The baseline characteristics
of this specific population in the 3 treatment groups were
similar in terms of the main prognostic parameters. When
the older group was compared with the younger group, ex-
cept for age, the other main parameters were similar in
frequency, despite sex, smoking status, and triglyceride
profile, which differed significantly between these age
groups.gery c November 2013
FIGURE 2. Ten-year overall survival in the 2 age groups from the MASS II trial (A) and in each treatment strategy comparing the age groups: MT (B), PCI
(C), and CABG (D).
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in patients aged 65 years or more demonstrated similar
overall mortality. This is similar to the findings of other tri-
als, such as the analysis of elderly patients from the Bypass
Angioplasty Revascularization Intervention (BARI)15 and
Stent or Surgery18 trials, although these studies only com-
pared PCI with CABG.
Our mortality results also were in accordance with the
results of BARI 2D age study.21 Although patients selected
were all diabetic, this study demonstrated similar mortality
rates with both strategies (MT vs intervention) in the
subgroup of patients aged more than 70 years.
Moreover, in a prespecified analysis of clinical outcomes
by age from the Clinical Outcomes Utilizing Revasculariza-
tion and Aggressive druG Evaluation trial,19 PCI plus MT
compared with MT alone resulted in similar survivals in
older patients in a median 4.6 years of follow-up (88%
survival in each strategy).The Journal of Thoracic and CarHowever, an analysis of older patients from the Alberta
Provincial Project for Outcomes Assessment in Coronary
Heart Disease study13 showed better survival outcomes
for older patients who were referred to CABG and
PCI treatments compared with MT. The largest risk
reductions were noted in the oldest group of patients.
Meanwhile, this was a cohort study, and it included
patients with acute coronary syndromes and left ventric-
ular dysfunction, clinical situations that favor revascular-
ization strategies.
In accordance with the Alberta Provincial Project for
Outcomes Assessment in Coronary Heart Disease study,13
an analysis of elderly patients from the Coronary Artery
Surgery Study showed better survival for CABG recipients
compared with MT recipients at 6-year follow-up, although
that was a nonrandomized study and even the authors
concluded that the 2 treatment groups differed substantially
with regard to important baseline characteristics.20diovascular Surgery c Volume 146, Number 5 1109
FIGURE 3. Survival free of acute MI in the 2 age groups from the MASS II trial (A) and in each treatment strategy comparing the age groups: MT (B), PCI
(C), and CABG (D).
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CABG in 189,793 patients aged 65 years or more with mul-
tiarterial CAD, mortality was similar between these 2 treat-
ments at 1 year, but at 4 years there was a lower adjusted
mortality with CABG treatment. However, this was a non-
randomized study.
To date, on the basis of these trials and our data, none of
the therapeutic options for chronic CAD treatment in pa-
tients aged 65 years or more seem to be superior to the
others in terms of overall mortality. Our study highlights
the importance of MT as a safe and possible treatment op-
tion to this specific population and brings results from
long-term follow-up.
In our study, CABG recipients had a lower incidence of
combined major cardiovascular events, especially related
to fewer additional coronary interventions. Older patients
in medical and angioplasty groups had rates of 41% and1110 The Journal of Thoracic and Cardiovascular Sur42%, respectively, of new mechanical interventions in 10
years compared with only 9% in CABG recipients. These
results are also similar to those of other trials, such as the
BARI,15 Stent or Surgery,18 and Trial of Invasive versus
Medical Therapy in the Elderly.23 In the Trial of Invasive
versus Medical Therapy in the Elderly, very old patients
(mean age, 80 years) who were assigned to MT had similar
overall mortality compared with the invasive group, but
they had a greater than 50% chance of late nonfatal events,
mainly hospitalizations for refractory symptoms with the
need for late revascularization.
In our analysis, PCI-treated elderly patients had a higher
incidence of MI compared with MT and CABG (23% PCI
vs 18% MT vs 10% CABG), although this was not statis-
tically significant (P ¼ .17). In another study,18 the inci-
dence of MI was similar between treatment groups in the
elderly.gery c November 2013
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tional interventions was high in PCI-treated elderly pa-
tients, as high as in the medically treated group (58% vs
59%, respectively).
Thus, in elderly patients from the MASS II trial, PCI
treatment did not confer any additional advantage over
MT in terms of overall mortality, MI, and angina requiring
additional interventions. These results are also similar to the
findings of the Clinical Outcomes Utilizing Revasculariza-
tion and Aggressive druG Evaluation elderly analysis.19
When we analyzed the main cardiac events in the older
group compared with the younger group, the event rates
were higher in the elderly patients, and this also occurred in-
dependently of the treatment strategy. Even after multivar-
iate analysis, age was still an independent factor related to
a worse prognosis. This was confirmed by other treatment
studies.15,20
There was no difference between the 2 age groups in
terms of additional coronary interventions, even when strat-
ified by treatment options. However, when we analyzed the
occurrence of MI, the older group of patients receiving PCI
treatment had a higher incidence of MI compared with the
younger group (23% vs 8.3%, P¼ .004), and even after ad-
justment for baseline differences, this finding did not
change. This difference did not occur in the MT and
CABG groups.
These results contrast with those reported by Kelsey and
colleagues,24 who found in a 2-year follow-up registry
study similar rates of MI in elderly and younger patients
treated with PCI. However, this was a nonrandomized study,
and its short outcomes follow-up probably did not detect
a late progression of CAD. In a retrospective study by
Nasser and colleagues,25 the occurrence of MI was similar
regarding age groups, but this was a 6-month follow-up
study, and there were fewer MI events.
Despite progressive declines in PCI complications in the
last 2 decades,26 long-term clinical outcomes related to PCI
treatment have been understudied in the literature, especially
in the older population. In a retrospective study by De Gre-
gorio and colleagues,27 older patients with CAD had a higher
incidence of angiographic restenosis compared with the
younger group (47% vs 28%, P ¼ .0007) 6 months after
PCI. However, in this study the older group had a higher pro-
portion of unstable angina, angina Canadian Cardiovascular
Society class III or IV, and severe coronary disease (higher
proportion of 3-vessel disease, ostial, calcified, and complex
lesions), which can explain these higher restenosis results.
In the current study, possible explanations for the higher
MI frequency in older patients undergoing PCI can be the
more diffuse atherosclerotic burden in this group. Although
we found the same proportion of 3-vessel coronary disease
in older and younger patients, we did not analyze other cor-
onary characteristics, such as frequency of ostial, calcified,
and complex lesions, generally more prevalent in olderThe Journal of Thoracic and Carpopulation. The analysis of the SYNTAX score28 from the
coronary arteriographies of our population would have
been helpful to evaluate more accurately possible anatomic
differences between the 2 age groups, which could explain
this finding of higher MI frequency in PCI-treated older pa-
tients. A lower frequency of complete revascularizations in
these patients can be another possible cause of our results.
Left ventricular dysfunction cannot explain these worse re-
sults, because all patients in theMASS II trial had preserved
ventricular systolic function.
This study provides important insights. Initial MT is safe
for older patients with multiarterial CAD with preserved
left ventricular function, because it resulted in similar rates
of death and MI when compared with PCI or CABG in
a long-term follow-up. In addition, as the population ages
and angioplasty extends its indication to patients with
higher-risk profiles, including older persons, this treatment
strategy has been increasingly indicated, but it should be
carefully evaluated. The finding of a greater incidence of
MI in PCI-treated older patients will need further studies,
but it is important to cardiologists to consider it when
they indicate percutaneous interventions based on only an-
atomic features. Finally, CABG does not prevent death or
MI in older patients with CAD, but it protects, especially
when there is the need for further coronary interventions.
Study Limitations
Our study has some limitations. In addition to the rela-
tively small sample size, which may lead to an inability to
detect treatment differences, it presents the problem of all
long-term follow-up studies, that is, the evolution of
standard care, especially related to improvements in inter-
ventions. In our study, angioplasty was performed with
bare-metal stents and all CABGs were performed on-
pump. The absence of information on stroke is another
limitation of the present study, which may be relevant infor-
mation in older patients.
CONCLUSIONS
In this MASS II trial analysis, the treatment options for
patients with CAD who are aged 65 years or more yield
a similar overall survival. However, CABG in older patients
was associated with fewer subsequent coronary interven-
tions, whereas PCI treatment was associated with a higher
incidence of MI. Age was independently associated with
overall mortality.
The authors thank all members of the MASS II trial for the hard
work that was necessary to perform this study.
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